Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ. Bulitta JB, et al. Among authors: hanauske ar. Cancer Chemother Pharmacol. 2009 May;63(6):1035-48. doi: 10.1007/s00280-008-0828-1. Epub 2008 Sep 13. Cancer Chemother Pharmacol. 2009. PMID: 18791717 Clinical Trial.
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ. Bulitta JB, et al. Among authors: hanauske ar. Cancer Chemother Pharmacol. 2009 May;63(6):1049-63. doi: 10.1007/s00280-008-0827-2. Epub 2008 Sep 13. Cancer Chemother Pharmacol. 2009. PMID: 18791718 Clinical Trial.
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, Punt C, Verweij J, van Oosterom A, Morant R, Wanders J, Hanauske AR. Pavlidis N, et al. Among authors: hanauske ar. Cancer Chemother Pharmacol. 2000;46(2):167-71. doi: 10.1007/s002800000134. Cancer Chemother Pharmacol. 2000. PMID: 10972487 Clinical Trial.
Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours.
Bos AM, de Vries EG, Dombernovsky P, Aamdal S, Uges DR, Schrijvers D, Wanders J, Roelvink MW, Hanauske AR, Bortini S, Capriati A, Crea AE, Vermorken JB. Bos AM, et al. Among authors: hanauske ar. Cancer Chemother Pharmacol. 2001 Nov;48(5):361-9. doi: 10.1007/s002800100350. Cancer Chemother Pharmacol. 2001. PMID: 11761453 Clinical Trial.
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR, Piccart M; European Organization for Research and Treatment of Cancer Early Clinical Studies Group. Eskens FA, et al. Among authors: hanauske ar. J Clin Oncol. 2001 Feb 15;19(4):1167-75. doi: 10.1200/JCO.2001.19.4.1167. J Clin Oncol. 2001. PMID: 11181683 Clinical Trial.
Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
Bakker M, Droz JP, Hanauske AR, Verweij J, van Oosterom AT, Groen HJ, Pacciarini MA, Domenigoni L, van Weissenbruch F, Pianezzola E, de Vries EG. Bakker M, et al. Among authors: hanauske ar. Br J Cancer. 1998;77(1):139-46. doi: 10.1038/bjc.1998.22. Br J Cancer. 1998. PMID: 9459159 Free PMC article. Clinical Trial.
119 results